Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01FSX
|
|||
| Drug Name |
REGN5093
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Non-small-cell lung cancer [ICD-11: 2C25.Y; ICD-9: 162] | Phase 1 | [1] | |
| Company |
Regeneron Pharmaceuticals
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04077099) REGN5093 in Patients With MET-Altered Advanced Non-Small Cell Lung Cancer. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Regeneron Pharmaceuticals. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.